Compare PLRX & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLRX | NEPH |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.1M | 49.4M |
| IPO Year | 2020 | 2004 |
| Metric | PLRX | NEPH |
|---|---|---|
| Price | $0.88 | $3.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $2.67 | ★ $6.25 |
| AVG Volume (30 Days) | ★ 371.2K | 34.6K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.97 | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | N/A | ★ $18,789,000.00 |
| Revenue This Year | N/A | $17.81 |
| Revenue Next Year | N/A | $15.90 |
| P/E Ratio | ★ N/A | $29.92 |
| Revenue Growth | N/A | ★ 32.67 |
| 52 Week Low | $0.96 | $2.66 |
| 52 Week High | $1.95 | $6.42 |
| Indicator | PLRX | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 24.98 | 42.55 |
| Support Level | N/A | $2.86 |
| Resistance Level | $1.37 | $3.78 |
| Average True Range (ATR) | 0.04 | 0.31 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 1.59 | 41.32 |
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.